Tumour lysis syndrome (Q40165): Difference between revisions
From determinar.ia.br - Determine suas informações
Created a new Item |
Changed an Item |
||||||||||||||
| (7 intermediate revisions by the same user not shown) | |||||||||||||||
| description / pt-br | description / pt-br | ||||||||||||||
Grupo de complicações metabólicas que podem ocorrer após o tratamento do câncer, geralmente linfomas e leucemias, e às vezes até mesmo sem tratamento. Essas complicações são causadas pelos produtos de degradação das células cancerosas mortas e incluem hipercalemia, hiperfosfatemia, hiperuricemia e hiperuricosúria, hipocalcemia e consequente nefropatia aguda por ácido úrico e insuficiência renal aguda. | |||||||||||||||
| description / en | description / en | ||||||||||||||
This is a group of metabolic complications that can occur after treatment of cancer, usually lymphomas and leukaemias, and sometimes even without treatment. These complications are caused by the breakdown products of dying cancer cells and include hyperkalaemia, hyperphosphataemia, hyperuricaemia and hyperuricosuria, hypocalcaemia, and consequent acute uric acid nephropathy and acute renal failure. | |||||||||||||||
| Property / Canonical URI | |||||||||||||||
| Property / Canonical URI: https://id.who.int/icd/entity/1913126571 / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / CURIE | |||||||||||||||
CID11:5D01 | |||||||||||||||
| Property / CURIE: CID11:5D01 / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / Canary Token | |||||||||||||||
dki-india-5D01 | |||||||||||||||
| Property / Canary Token: dki-india-5D01 / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / Verification Status | |||||||||||||||
Concluído | |||||||||||||||
| Property / Verification Status: Concluído / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / Knowledge Architect | |||||||||||||||
| Property / Knowledge Architect: https://pauloleads.com.br/cases-publicos/ / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / Collection date | |||||||||||||||
13 August 2026
| |||||||||||||||
| Property / Collection date: 13 August 2026 / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / Linked ICD 10 | |||||||||||||||
| Property / Linked ICD 10: E88.3 / rank | |||||||||||||||
Normal rank | |||||||||||||||
Latest revision as of 05:52, 13 August 2026
This is a group of metabolic complications that can occur after treatment of cancer, usually lymphomas and leukaemias, and sometimes even without treatment. These complications are caused by the breakdown products of dying cancer cells and include hyperkalaemia, hyperphosphataemia, hyperuricaemia and hyperuricosuria, hypocalcaemia, and consequent acute uric acid nephropathy and acute renal failure.
| Language | Label | Description | Also known as |
|---|---|---|---|
| default for all languages | 5D01 |
||
| English | Tumour lysis syndrome |
This is a group of metabolic complications that can occur after treatment of cancer, usually lymphomas and leukaemias, and sometimes even without treatment. These complications are caused by the breakdown products of dying cancer cells and include hyperkalaemia, hyperphosphataemia, hyperuricaemia and hyperuricosuria, hypocalcaemia, and consequent acute uric acid nephropathy and acute renal failure. |
Statements
CID11:5D01
0 references
dki-india-5D01
0 references
Concluído
0 references
13 August 2026
0 references
